Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triplenegative early breast cancer

Annals of Oncology

Volumn 28, Issue 4, 2017, Pages 754-760

  Bell, R ^a   Brown, J ^b   Parmar, M ^c   Toi, M ^d   Suter, T ^e   Steger, G G ^f   Pivot, X ^g   Mackey, J ^h   Jackisch, C ⁱ   Dent, R ^j,k   Hall, P ^l   Xu, N ^m   Morales, L ^m   Provencher, L ⁿ   Hegg, R ^o   Vanlemmens, L ^p   Kirsch, A ^q   Schneeweiss, A ^r   Masuda, N ^s   Overkamp, F ^t   Cameron, D ^u   more..

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d KYOTO UNIVERSITY   (Japan)

^e BERN UNIVERSITY HOSPITAL   (Switzerland)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^h Cross Center Institute   (Canada)

ⁱ SANA KLINIKUM OFFENBACH   (Germany)

^j National Cancer Center   (Singapore)

^k UNIVERSITY OF TORONTO   (Canada)

^l UNIVERSITY OF LEEDS   (United Kingdom)

^m F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁿ LAVAL UNIVERSITY   (Canada)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p CENTRE OSCAR LAMBRET   (France)

^q Onkologischer Schwerpunktam Oskar Helene Heim   (Germany)

^r UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^s OSAKA NATIONAL HOSPITAL   (Japan)

^t Oncologianova   (Germany)

^u UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

Bevacizumab; Breast cancer; Chemotherapy; Survival; Triple negative

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85019144026     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw665     Document Type: Article

References (32)

1. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
2. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
3. Miles D, Cameron D, Bondarenko I et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer 2017; 70: 146-155.
4. Robert NJ, Diéras V, Glaspy J et al. RIBBON-1: randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
5. Brufsky AM, Hurvitz S, Perez E et al. RIBBON-2: a randomized, doubleblind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29: 4286-4293.
6. von Minckwitz G, Puglisi F, Cortes J et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 1269-1278.
7. Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-320.
8. von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
9. Earl HM, Hiller L, Dunn JA et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol 2015; 16: 656-666.
10. Sikov WM, Berry DA, Perou CM et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33: 13-21.
11. Nahleh ZA, Barlow WE, Hayes DF et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nabpaclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 2016; 158: 485-495.
12. de Gramont A, Van Cutsem E, Schmoll HJ et al. Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225-1233.
13. Allegra CJ, Yothers G, O'Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-16.
14. Allegra CJ, Yothers G, O'Connell MJ et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013; 31: 359-364.
15. Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013; 14: 933-942.
16. Slamon DJ, Swain SM, Buyse M et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab 6 bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. Cancer Res 2013; 73: abstract S1-03.
17. Miller K, O'Neill AM, Dang CT et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol 2014; 32(Suppl 5s): abstract 500.
18. Haas NB, Manola J, Uzzo RG et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387: 2008-2016.
19. Cortes J, Calvo V, Ramírez-Merino N et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 2012; 23: 1130-1137.
20. Bear HD, Tang G, Rastogi P et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 2015; 16: 1037-1048.
21. von Minckwitz G, Loibl S, Untch M, GBG/AGO-B study groups et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44- GeparQuinto). Ann Oncol 2014; 25: 2363-2372.
22. Kerbel RS, Guerin E, Francia G et al. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastasis. Breast 2013; 22 (Suppl 2): S57-S65.
23. Spill F, Guerrero P, Alarcon T et al. Mesoscopic and continuum modelling of angiogenesis. J Math Biol 2015; 70: 485-532.
24. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
25. Perez-Garcia J, Cortes J. Adjuvant bevacizumab: positive data from a negative trial. Lancet Oncol 2013; 14: 910-911.
26. Mountzios G, Pentheroudakis G, Carmeliet P. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol Ther 2014; 141: 117-124.
27. Paez-Ribes M, Man S, Xu P, Kerbel RS. Potential proinvasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy. Clin Cancer Res 2015; 21: 5488-5498.
28. Gligorov J, Doval D, Bines J et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1351-1360.
29. Toi M, Lee S-J, Lee ES et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Res 2016; 76(4 Suppl): abstract S1-07.
30. Bianchini G, Balko JM, Mayer IA et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016; 13(11): 674-690.
31. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
32. Molinero L, Yu J, Li C et al. Analysis of molecular prognostic factors associated with tumor immune and stromal microenvironment in BEATRICE, an open-label phase 3 trial in early triple-negative breast cancer (eTNBC). Cancer Res 2016; 76(4 Suppl): abstract S1-01.